Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 14 · below the Ichimoku cloud · RSI 33 · MACD below its signal · 7% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $514.7K | 0.00% | 164.45K | +137% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a VERU trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 12, 2026 | Barnette K Gary Ph.D.Officer | Purchase at price 2.69 per share. | 1.8K | $4.84K |
| Feb 18, 2025 | Rankowitz Michael LDirector | Purchase at price 0.55 - 0.58 per share. | 150K | $84.35K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 18.2 | 2.0 | -14.3 | 1.8 | 5.3 | 32.1 | -28.4 | 25.0 | -5.0 | -17.7 | +2.3% | ||
| 2025 | -13.8 | -7.1 | -5.8 | 10.2 | -5.6 | 13.7 | -17.2 | -32.3 | 16.9 | -22.4 | -15.9 | -13.7 | −67.1% |
| 2024 | -31.9 | 24.5 | 14.8 | 92.9 | -25.2 | -16.8 | 11.9 | -12.8 | -6.1 | -1.3 | -6.6 | -8.5 | −9.7% |
| 2023 | 9.1 | -31.3 | -70.7 | 9.5 | -22.0 | 20.2 | 5.9 | -17.5 | -30.8 | 25.0 | 6.7 | -25.0 | −86.4% |
| 2022 | -11.7 | 7.5 | -13.6 | 142.7 | 10.4 | -12.7 | 7.1 | 26.4 | -24.7 | 6.3 | -53.6 | -7.0 | −10.4% |
| 2021 | 2.0 | 56.7 | -22.0 | -18.0 | -0.1 | -8.6 | -14.9 | 29.8 | -4.4 | -4.2 | -8.2 | -21.5 | −31.9% |
| 2020 | 4.5 | 18.0 | -20.8 | -1.2 | 15.5 | -10.5 | -15.3 | -2.1 | -5.4 | -3.8 | 20.6 | 184.5 | +158.2% |
| 2019 | 10.0 | -3.9 | -1.4 | -4.8 | 41.7 | 8.1 | 6.1 | -12.8 | 9.6 | -9.3 | 8.2 | 58.0 | +139.3% |
| 2018 | 4.4 | 16.8 | 30.2 | 9.4 | 5.1 | -2.9 | -4.5 | 3.1 | -28.6 | -14.8 | 24.0 | -6.7 | +22.8% |
| 2017 | 12.1 | -1.0 | 0.0 | 2.0 | 13.6 | -10.3 | 14.3 | 34.2 | 64.6 | -49.1 | -20.0 | 5.6 | +25.3% |
| 2016 | -11.0 | 49.6 | -3.1 | -31.6 | 4.7 | -6.0 | 0.0 | 4.0 | -6.9 | -22.1 | 17.9 | -18.7 | −37.2% |
| 2015 | -3.3 | -8.4 | -18.4 | 3.2 | -18.5 | -24.4 | -1.1 | -21.3 | 12.9 | 8.2 | -9.9 | -5.8 | −63.0% |
| 2014 | -11.3 | -8.4 | 12.3 | -2.6 | -22.2 | -6.3 | -29.0 | -1.3 | -9.6 | 30.9 | -6.8 | -8.0 | −53.9% |
| 2013 | 6.7 | -7.3 | 2.0 | 5.9 | 21.4 | 5.9 | -6.9 | -6.3 | 14.7 | -3.4 | -3.8 | -7.2 | +18.4% |
| 2012 | 14.6 | -4.8 | 10.2 | 10.9 | -6.5 | 4.4 | 4.8 | 9.8 | 5.9 | -2.1 | 2.9 | -0.3 | +59.2% |
| 2011 | -9.5 | -1.0 | -2.2 | -5.2 | 7.0 | -1.2 | -7.8 | -6.5 | -5.3 | 11.5 | -1.1 | 0.2 | −20.7% |
| 2010 | 16.3 | 2.7 | 26.9 | -10.9 | -8.6 | -11.1 | -2.1 | -6.3 | 8.2 | 8.0 | 2.7 | -0.4 | +20.3% |
| 2009 | -9.9 | 2.2 | 12.8 | -1.4 | 7.7 | 22.4 | 30.6 | 9.3 | -26.3 | -8.3 | 17.9 | -13.4 | +33.2% |
| 2008 | -9.6 | 10.2 | -4.6 | 3.2 | 1.6 | 1.9 | -3.8 | 14.9 | 4.1 | -5.2 | -12.8 | 40.9 | +36.0% |
| 2007 | 33.1 | -2.4 | 11.5 | 32.3 | -18.3 | -10.0 | 1.4 | -8.6 | 16.9 | 27.7 | -14.7 | 2.0 | +69.5% |
Buy / hold / sell counts
Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle loss in sarcopenic obese and overweight elderly patients; Enobosarm, an oral selective androgen receptor modulator for the treatment of AR+ ER+ HER2- metastatic breast cancer; and sabizabulin, a microtubule disruptor for the treatment of hospitalized patients with viral lung infection at high risk for viral induced ARDS and death. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.